Literature DB >> 1590706

Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae.

S G Franzblau1, A N Biswas, E B Harris.   

Abstract

The activity of fusidic acid against Mycobacterium leprae was studied in axenic medium and in bacilli residing within mouse peritoneal macrophages. Activity was assessed by subsequent quantitation of bacillary radiorespirometric activity. Significant inhibition in both systems was observed at 0.156 micrograms/ml, and an approximately 50% reduction in activity occurred after exposure to 1.25 to 2.5 micrograms/ml. The excellent human pharmacokinetics and in vitro activity of fusidic acid against the leprosy bacillus warrant a clinical trial of this drug for leprosy.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1590706      PMCID： PMC189233          DOI： 10.1128/AAC.36.1.92

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Effect of several anti-leprosy drugs on multiplication of human leprosy bacilli in footpads of mice.

Authors:  C C SHEPARD; Y T CHANG
Journal:  Proc Soc Exp Biol Med       Date:  1962-03

2.  Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation.

Authors:  A M Taburet; J Guibert; M D Kitzis; H Sorensen; J F Acar; E Singlas
Journal:  J Antimicrob Chemother       Date:  1990-02       Impact factor: 5.790

3.  Susceptibility of mycobacteria to fusidic acid.

Authors:  S E Hoffner; B Olsson-Liljequist; K J Rydgård; S B Svenson; G Källenius
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-04       Impact factor: 3.267

4.  Penetration of antimicrobials into tissue culture cells and leucocytes.

Authors:  K N Brown; A Percival
Journal:  Scand J Infect Dis Suppl       Date:  1978

5.  Interaction between rifampin and fusidic acid against methicillin-resistant coagulase-positive and -negative staphylococci.

Authors:  B F Farber; Y C Yee; A W Karchmer
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

6.  Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.

Authors:  D Van Caekenberghe
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

Review 7.  The antimicrobial activity of fusidic acid.

Authors:  L Verbist
Journal:  J Antimicrob Chemother       Date:  1990-02       Impact factor: 5.790

8.  In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae.

Authors:  S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  L-arginine-dependent macrophage effector functions inhibit metabolic activity of Mycobacterium leprae.

Authors:  L B Adams; S G Franzblau; Z Vavrin; J B Hibbs; J L Krahenbuhl
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

10.  Effects of activated macrophages on Mycobacterium leprae.

Authors:  N Ramasesh; L B Adams; S G Franzblau; J L Krahenbuhl
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441
View more
  5 in total

Review 1.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

2.  Mycobacterium leprae is naturally resistant to PA-824.

Authors:  Ujjini H Manjunatha; Ramanuj Lahiri; Baljit Randhawa; Cynthia S Dowd; James L Krahenbuhl; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

3.  Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

Authors:  R S Witzig; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

4.  In vitro activities of ceftriaxone and fusidic acid against 13 isolates of Coxiella burnetii, determined using the shell vial assay.

Authors:  H Torres; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

5.  Clinical trial of fusidic acid for lepromatous leprosy.

Authors:  S G Franzblau; G P Chan; B G Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; R F Calvo; D L Williams; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.